Abstract: Cells for increased collagen production are engineered by a novel CRISPR cellular engineering process. The process can be carried out using human cells or even patient-harvested cells. Collagen produced by the cells has a low risk of immunogenicity when implanted into human patients compared to collagen produced by non-human cells. Cell culture media including chemical additives are also provided to have a further positive effect on collagen production.

Abstract: Compositions and methods are provided to accelerate and improve wound repair and reconstruction of connective tissue structures, including tendons, by assembly of collagen using liquid crystalline collagen. The compositions and methods can be used to treat various forms of connective tissue injury or to prevent or slow degeneration to vulnerable tendons that are generally refractory to repair.